U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07105111) titled 'A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor' on July 29.
Brief Summary: This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Schizophrenia
Schizoaffective Disorder
Bipolar Disorder
Major Depressive Disorder
Tardive Dyskinesia
Intervention:
DRUG: Valbenazine
Valbenazine caps...